MetaCap

Avalyn Pharma (AVLN) vs Generate Biomedicines (GENB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avalyn Pharma is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVLN-3.70%GENB-24.47%
+66%+18%-29%
Apr 30, 20261 yearNov 20, 2026
AVLN-4.83%GENB-27.45%
+35%+2%-30%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVLN versus GENB key metrics
MetricAVLNGENB
Share price$28.40$9.54
Market cap$1.26B$1.23B
1-day change-1.05%-8.00%
EPS (TTM)$-3.96$-2.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$40.17$22.67
52-week low$22.24$9.40
Distance from 52-week high-29.30%-57.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+114.79%+183.02%
Average volume352.95K1.24M
Shares outstanding44.52M129.10M
Employees56312
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Avalyn Pharma

AVLN stock →

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

About Generate Biomedicines

GENB stock →

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees

AVLN vs GENB FAQ

Which is bigger, Avalyn Pharma or Generate Biomedicines?

Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.26B compared with $1.23B for Generate Biomedicines (GENB).

Are Avalyn Pharma and Generate Biomedicines in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons